Rapidly dissolving Lacidipine (cas 103890-78-4) nanoparticle strips for transbuccal administration

Add time:07/22/2019    Source:sciencedirect.com

The purpose of this study was to prepare fast-dissolving film strips containing Lacidipine (cas 103890-78-4) (LCDP) nanoparticles for transbuccal administration. Nanoparticles were prepared using the solvent-antisolvent sonoprecipitation technique. The influence of different antisolvent phase stabilizers on particle size was studied. Optimised nanosuspension was incorporated into films fabricated by solvent casting with HPMC, HPC, PVA and combinations of these polymers. The physical, mechanical properties and behaviour of these films were assessed using in vitro and ex vivo studies. The nanosuspension prepared with the stabilizer sodium lauryl sulphate was selected for incorporation in further film formulations. Films fabricated with HPMC E 15 and HPMC E5 - PVA with PEG 400 as plasticizer were found to have superior mechanical and disintegration properties. SEM images of films showed that almost perfect sphere-shaped nanoparticles were distributed in the polymeric matrix. Permeation studies across porcine buccal mucosa found a 9.5 fold higher degree of permeation of LCDP from LCDP-FD 2 formulation compared to the plain drug.

We also recommend Trading Suppliers and Manufacturers of Lacidipine (cas 103890-78-4). Pls Click Website Link as below: cas 103890-78-4 suppliers

Prev:Lacidipine (cas 103890-78-4) attenuates TNF-α-induced cardiomyocyte apoptosis
Next:Co-amorphous solid dispersion systems of Lacidipine (cas 103890-78-4)-spironolactone with improved dissolution rate and enhanced physical stability)